ES2914876T3 - Procesos para la preparación de (S)-3-(4-((4-(morfolinometil)bencil)oxi)-1-oxoisoindolin-2-il)piperidin-2, 6-diona y formas farmacéuticas aceptables de las mismas - Google Patents

Procesos para la preparación de (S)-3-(4-((4-(morfolinometil)bencil)oxi)-1-oxoisoindolin-2-il)piperidin-2, 6-diona y formas farmacéuticas aceptables de las mismas Download PDF

Info

Publication number
ES2914876T3
ES2914876T3 ES18206764T ES18206764T ES2914876T3 ES 2914876 T3 ES2914876 T3 ES 2914876T3 ES 18206764 T ES18206764 T ES 18206764T ES 18206764 T ES18206764 T ES 18206764T ES 2914876 T3 ES2914876 T3 ES 2914876T3
Authority
ES
Spain
Prior art keywords
compound
formula
benzyl
acid
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES18206764T
Other languages
English (en)
Spanish (es)
Inventor
John Fitzgerald Traverse
Chengmin Zhang
Gregg B Feigelson
Benjamin M Cohen
William Wei-Hwa Leong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Corp
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Application granted granted Critical
Publication of ES2914876T3 publication Critical patent/ES2914876T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ES18206764T 2012-08-09 2013-08-08 Procesos para la preparación de (S)-3-(4-((4-(morfolinometil)bencil)oxi)-1-oxoisoindolin-2-il)piperidin-2, 6-diona y formas farmacéuticas aceptables de las mismas Active ES2914876T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261681477P 2012-08-09 2012-08-09

Publications (1)

Publication Number Publication Date
ES2914876T3 true ES2914876T3 (es) 2022-06-17

Family

ID=49035933

Family Applications (2)

Application Number Title Priority Date Filing Date
ES18206764T Active ES2914876T3 (es) 2012-08-09 2013-08-08 Procesos para la preparación de (S)-3-(4-((4-(morfolinometil)bencil)oxi)-1-oxoisoindolin-2-il)piperidin-2, 6-diona y formas farmacéuticas aceptables de las mismas
ES13753229T Active ES2712652T3 (es) 2012-08-09 2013-08-08 Procesos para la preparación de (S)-3-4-((4-(morfolinometil) bencil) oxi) -1-oxoisoindolin-2il-) piperidin-2, 6-diona y formas farmacéuticas aceptables de las mismas

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES13753229T Active ES2712652T3 (es) 2012-08-09 2013-08-08 Procesos para la preparación de (S)-3-4-((4-(morfolinometil) bencil) oxi) -1-oxoisoindolin-2il-) piperidin-2, 6-diona y formas farmacéuticas aceptables de las mismas

Country Status (19)

Country Link
US (2) US9309220B2 (enExample)
EP (2) EP2882736B1 (enExample)
JP (1) JP6444866B2 (enExample)
KR (1) KR20150041650A (enExample)
CN (1) CN104718202B (enExample)
AU (1) AU2013299559B2 (enExample)
BR (1) BR112015002183A2 (enExample)
CA (2) CA2879151C (enExample)
CR (1) CR20150051A (enExample)
EC (1) ECSP15004585A (enExample)
ES (2) ES2914876T3 (enExample)
HK (1) HK1211577A1 (enExample)
IL (1) IL236925A0 (enExample)
IN (1) IN2015DN00845A (enExample)
MX (2) MX2015001633A (enExample)
PH (1) PH12015500214A1 (enExample)
RU (1) RU2015108057A (enExample)
SG (1) SG11201500984QA (enExample)
WO (1) WO2014025978A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG183257A1 (en) 2010-02-11 2012-09-27 Celgene Corp Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
EP2699091B1 (en) 2011-03-28 2017-06-21 DeuteRx, LLC 2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds
AU2014205043B2 (en) 2013-01-14 2018-10-04 Deuterx, Llc 3-(5-substituted-4-oxoquinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives
US9695145B2 (en) 2013-01-22 2017-07-04 Celgene Corporation Processes for the preparation of isotopologues of 3-(4-((4- morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable salts thereof
AU2014236597A1 (en) 2013-03-14 2015-09-24 Deuterx, Llc 3-(substituted-4-oxo-quinazolin-3(4H)-yl)-3-deutero-piperidine-2,6-dione derivatives
US9809603B1 (en) 2015-08-18 2017-11-07 Deuterx, Llc Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same
MX2020002010A (es) 2017-08-21 2020-07-13 Celgene Corp Procesos para la preparacion de 4,5-diamino-5-oxopentanoato de (s)-terc-butilo.
CA3114401A1 (en) 2018-10-01 2020-04-09 Celgene Corporation Combination therapy for the treatment of cancer
CN110194760B (zh) * 2019-05-27 2021-08-17 浙江农林大学暨阳学院 制备3-亚苄基-2-(7’-喹啉)-2,3-二氢-异吲哚-1-酮类化合物的方法
KR20220110243A (ko) * 2019-12-02 2022-08-05 셀진 코포레이션 암의 치료를 위한 요법
CN113896711A (zh) 2020-07-06 2022-01-07 北京诺诚健华医药科技有限公司 杂环类免疫调节剂
US20260098035A1 (en) 2022-09-20 2026-04-09 Celgene Corporation Salts and solid forms of (s)- or racemic 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and methods of using the same
CN121002005A (zh) * 2023-04-11 2025-11-21 上海科胜药物研发有限公司 一种芳基甲氧基异吲哚啉衍生物的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7629360B2 (en) * 1999-05-07 2009-12-08 Celgene Corporation Methods for the treatment of cachexia and graft v. host disease
NZ554068A (en) * 2004-09-03 2009-07-31 Celgene Corp Processes for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindo-lines
PL1907373T3 (pl) * 2005-06-30 2013-05-31 Celgene Corp Sposób wytwarzania związków 4-amino-2-(2,6-diokso-piperydyn-3-ylo)izoindolino-1,3-dionu
CA2681633C (en) 2007-03-20 2018-01-09 Celgene Corporation 4'-o-substituted isoindoline derivatives and compositions comprising and methods of using the same
SG183257A1 (en) * 2010-02-11 2012-09-27 Celgene Corp Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
US8877932B2 (en) 2010-03-08 2014-11-04 Natco Pharma Limited Anhydrous lenalidomide form-I
US9085551B2 (en) 2012-02-21 2015-07-21 Celgene Corporation Solid forms of 3-(4-nitro-1-oxisoindolin-2-yl)piperidine-2,6-dione

Also Published As

Publication number Publication date
CA2879151C (en) 2021-03-30
JP6444866B2 (ja) 2018-12-26
HK1211577A1 (en) 2016-05-27
ECSP15004585A (es) 2015-12-31
EP3466942A1 (en) 2019-04-10
MX385058B (es) 2025-03-14
US9975872B2 (en) 2018-05-22
EP2882736B1 (en) 2019-01-09
IN2015DN00845A (enExample) 2015-06-12
BR112015002183A2 (pt) 2017-07-04
CA2879151A1 (en) 2014-02-13
AU2013299559A1 (en) 2015-02-05
CA3108974C (en) 2023-04-04
WO2014025978A1 (en) 2014-02-13
ES2712652T3 (es) 2019-05-14
US20160251333A1 (en) 2016-09-01
US20140046058A1 (en) 2014-02-13
US9309220B2 (en) 2016-04-12
KR20150041650A (ko) 2015-04-16
CA3108974A1 (en) 2014-02-13
RU2015108057A (ru) 2016-09-27
PH12015500214A1 (en) 2015-04-27
CR20150051A (es) 2015-05-11
SG11201500984QA (en) 2015-04-29
IL236925A0 (en) 2015-03-31
MX2015001633A (es) 2015-04-08
JP2015524481A (ja) 2015-08-24
EP2882736A1 (en) 2015-06-17
AU2013299559B2 (en) 2017-08-17
CN104718202A (zh) 2015-06-17
EP3466942B1 (en) 2022-04-20
CN104718202B (zh) 2018-11-20

Similar Documents

Publication Publication Date Title
ES2712652T3 (es) Procesos para la preparación de (S)-3-4-((4-(morfolinometil) bencil) oxi) -1-oxoisoindolin-2il-) piperidin-2, 6-diona y formas farmacéuticas aceptables de las mismas
JP7846735B2 (ja) 甲状腺ホルモン受容体ベータアゴニスト化合物
CN114174281B (zh) 细胞周期蛋白依赖性激酶7(cdk7)的降解剂及其用途
CA2632194A1 (en) N4-phenyl-quinazoline-4-amine derivatives and related compounds as erbb type i receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases
WO2014017938A2 (en) Process for the synthesis of substituted urea compounds
JP5892550B2 (ja) 縮合イミダゾール誘導体
ES2641258T3 (es) Compuesto heterocíclico bicíclico
JP2016522240A (ja) RORcモジュレーターとしてのアリールスルタム誘導体
CA2856824A1 (en) Cyclic urea derivatives as androgen receptor antagonists
Munin et al. Synthesis, biological evaluation and structure–activity relationships of new phthalazinedione derivatives with vasorelaxant activity
US11453657B2 (en) Compounds for the treatment of parasitic infections
EA015152B1 (ru) О-замещенные производные дибензилмочевины в качестве антагонистов рецепторов trpv1
CN122036722A (zh) γ-四氢咔啉的异羟肟酸类化合物及其制备方法和应用
CN121735859A (zh) 一种三唑啉酮类化合物及其制备方法和应用